{"result": "(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitoma is a type of tumor that secretes catecholamines, often diagnosed through various medical tests and treatments.)\n##\n(\"entity\"<|>DÍAZ PÉREZ JA<|>PERSON<|>Díaz Pérez JA is an author who contributed to the understanding of feocromocitoma and paraganglioma in the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>CRESPO HERNÁNDEZ I<|>PERSON<|>Crespo Hernández I is an author who collaborated on the topic of feocromocitoma and paraganglioma in the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>EVENT<|>The Manual de Endocrinología y Nutrición is a medical reference that discusses various endocrine disorders, including feocromocitoma.)\n##\n(\"entity\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>EVENT<|>Harrison Principios de Medicina Interna is a comprehensive medical textbook that includes information on feocromocitoma and other internal medicine topics.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>UpToDate is a clinical decision support resource that provides information on the clinical presentation and diagnosis of pheochromocytoma.)\n##\n(\"relationship\"<|>DÍAZ PÉREZ JA<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Díaz Pérez JA contributed to the Manual de Endocrinología y Nutrición, discussing feocromocitoma and paraganglioma<|>8)\n##\n(\"relationship\"<|>CRESPO HERNÁNDEZ I<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Crespo Hernández I contributed to the Manual de Endocrinología y Nutrición, discussing feocromocitoma and paraganglioma<|>8)\n##\n(\"relationship\"<|>YOUNG WF, JR.<|>UPTODATE<|>Young WF, Jr. provides insights on pheochromocytoma in UpToDate, contributing to its clinical guidelines<|>7)\n##\n(\"relationship\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>FEOCROMOCITOMA<|>Harrison Principios de Medicina Interna includes information on feocromocitoma, discussing its diagnosis and treatment<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Larsen PR, Kronenberg HM, eds. Williams Textbook\n           review current through: Apr. 2019.                                                                                                      of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n         • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n           of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n\n\n\n278                                                                                                                                                                                                                                                                                279\n---\n                                                                                                                                                                                   SUPRARRENALES                                      5\n\n\n\n     5.4 Feocromocitoma                                                                                       mostrado su utilidad diagnóstica y terapéutica en los tumores secretores de catecolaminas\n                                                                                                              debido a su alta afinidad y captación por las células cromafines.\n                                                                                                              Referencias:\n       25     ¿Cuál de las siguientes afirmaciones es correcta respecto al feocromocitoma?                    • Díaz Pérez JA, Crespo Hernández I. Feocromocitoma y paraganglioma. Manual de Endocrinología y Nutrición. Disponible en:\n                                                                                                                https://manual.seen.es (última modificación: 24 de noviembre de 2015).\n              A. Las metanefrinas plasmáticas libres son una prueba muy sensible para el diagnóstico          • Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma:\n                                                                                                                an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.\n                  del feocromocitoma.                                                                         • Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios\n                                                                                                                de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2329-35.\n              B. En el tratamiento prequirúrgico del feocromocitoma debe administrarse primero                • Young WF, Jr. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n                  betabloqueantes y posteriormente bloqueadores alfaadrenérgicos.                               uptodate.com. Literature review current through: Apr. 2019.\n                                                                                                              • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n              C. Una posibilidad para el tratamiento del feocromocitoma maligno es el tratamiento               of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n                                                                                                              • Young WF, Jr, Kebebew E. Treatment of pheochromocytoma in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.\n                  con yodo-colesterol, que se administra en una dosis de 200 mCi.                               com. Literature review current through: Apr. 2019.\n              D.  El 25% de los feocromocitomas son bilaterales.\n\n\n\n                                                                                                          26  En relación con el diagnóstico de feocromocitoma, indique cuál de las siguientes\n              COMENTARIO                                                                                      afirmaciones es verdadera:\n              Los tumores secretores de catecolaminas que se originan en las células cromafines de la         A. Existen numerosas medicaciones, como los antidepresivos tricíclicos\n              médula suprarrenal y los ganglios simpáticos se conocen como feocromocitomas y para-                o los bloqueantes de los canales de calcio, que pueden interferir en la captación\n              gangliomas secretores de catecolaminas.                                                             de la metayodobencilguanidina (MIBG).\n              Los tumores secretores de catecolaminas son infrecuentes, con una incidencia anual de 2         B. La determinación de cromogranina A tiene una alta especificidad diagnóstica.\n              a 8 casos por millón de habitantes. Se producen con la misma frecuencia en ambos sexos,         C. La insuficiencia renal, aunque sea avanzada, no interfiere en la determinación\n              principalmente entre la tercera y quinta décadas de la vida. La mayoría de los tumores              de catecolaminas plasmáticas.\n              secretores de catecolaminas son esporádicos; sin embargo, hasta en un 40% de los casos\n              pueden identificarse mutaciones en línea germinal.                                              D.  La determinación de catecolaminas plasmáticas ofrece mayor fiabilidad diagnóstica\n                                                                                                                  que la determinación de metanefrinas en orina de 24 horas.\n              Aproximadamente, el 95% se localizan en el abdomen (85-90% localizados en las suprarre-\n              nales) y un 5-10% son múltiples\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>LARSEN PR<|>ORGANIZATION<|>Larsen PR is an organization involved in the publication of medical textbooks, including the Williams Textbook of Endocrinology.)\n##\n(\"entity\"<|>KRONENBERG HM<|>PERSON<|>Kronenberg HM is an editor of the Williams Textbook of Endocrinology, contributing to the field of endocrinology.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>EVENT<|>The Williams Textbook of Endocrinology is a comprehensive medical textbook that covers various aspects of endocrinology, including diagnosis and treatment of endocrine disorders.)\n##\n(\"entity\"<|>YOUNG WF, JR.<|>PERSON<|>Young WF, Jr. is a contributor to the Williams Textbook of Endocrinology, focusing on topics such as endocrine hypertension and pheochromocytoma.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is the location where the Williams Textbook of Endocrinology was published by Elsevier.)\n##\n(\"entity\"<|>ELSEVIER<|>ORGANIZATION<|>Elsevier is a publishing company that published the Williams Textbook of Endocrinology.)\n##\n(\"relationship\"<|>KRONENBERG HM<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Kronenberg HM is an editor of the Williams Textbook of Endocrinology, contributing to its content<|>8)\n##\n(\"relationship\"<|>YOUNG WF, JR.<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Young WF, Jr. contributed to the Williams Textbook of Endocrinology, providing insights on endocrine hypertension and pheochromocytoma<|>8)\n##\n(\"relationship\"<|>LARSEN PR<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Larsen PR is associated with the publication of the Williams Textbook of Endocrinology<|>7)\n##\n(\"relationship\"<|>ELSEVIER<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Elsevier published the Williams Textbook of Endocrinology, making it available to the medical community<|>9)\n##\n(\"relationship\"<|>PHILADELPHIA<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>The Williams Textbook of Endocrinology was published in Philadelphia<|>6)\n<|COMPLETE|>"}]}